{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:45:44Z","timestamp":1790711144783,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40256-025-00767-4","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:04:06Z","timestamp":1759327446000},"page":"157-163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of Tirzepatide on Cardiovascular Outcomes"],"prefix":"10.1007","volume":"26","author":[{"given":"Jessica","family":"Huston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dontia","family":"Orey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ashchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Ashchi","family":"Lachapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsey","family":"Ashchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Towfeeq","family":"Ashchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majdi","family":"Ashchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasim","family":"Deeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6401-4888","authenticated-orcid":false,"given":"Rebecca F.","family":"Goldfaden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"767_CR1","unstructured":"US Centers for Disease Control and Prevention. Type 2 diabetes. 16 Dec 2021. https:\/\/www.cdc.gov\/diabetes\/about\/about-type-2-diabetes.html. Accessed 20 Feb 2025."},{"key":"767_CR2","doi-asserted-by":"crossref","unstructured":"Zimmerman RS. Diabetes mellitus: management of microvascular and macrovascular complications. Cleveland Clinic Center for Continuing Education. Sept 2016. https:\/\/www.clevelandclinicmeded.com\/medicalpubs\/diseasemanagement\/endocrinology\/diabetes-mellitus\/. Accessed 20 Feb 2025.","DOI":"10.4103\/2230-8210.192910"},{"issue":"6","key":"767_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1358\/dof.2022.47.6.3373535","volume":"47","author":"AJ Sperry","year":"2022","unstructured":"Sperry AJ, Hardy J, Goldfaden RF, et al. Danuglipron, glucagon-like peptide 1 receptor agonist, treatment of type 2 diabetes, treatment of obesity. Drugs Future. 2022;47(6):407\u201318. https:\/\/doi.org\/10.1358\/dof.2022.47.6.3373535.","journal-title":"Drugs Future"},{"issue":"Suppl 1","key":"767_CR4","first-page":"S11","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes. Diabetes Care. 2021;44(Suppl 1):S11\u201324.","journal-title":"Diabetes Care"},{"key":"767_CR5","doi-asserted-by":"crossref","unstructured":"McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S. Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and metaanalysis. Diabetes Obes Metab. 2018;20(4):1040\u20133.","DOI":"10.1111\/dom.13160"},{"key":"767_CR6","unstructured":"Tucker ME. Half abandon metformin within a year of diabetes diagnosis. Medscape. 2021."},{"issue":"10","key":"767_CR7","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","volume":"298","author":"AM Lincoff","year":"2007","unstructured":"Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180\u20138. https:\/\/doi.org\/10.1001\/jama.298.10.1180.","journal-title":"JAMA"},{"issue":"8","key":"767_CR8","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1080\/00325481.2015.1090295","volume":"127","author":"CF Shaefer Jr","year":"2015","unstructured":"Shaefer CF Jr, Kushner P, Aguilar R. User\u2019s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015;127(8):818\u201326.","journal-title":"Postgrad Med"},{"issue":"8","key":"767_CR9","doi-asserted-by":"publisher","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","volume":"105","author":"JJ Holst","year":"2020","unstructured":"Holst JJ, Rosenkilde MM. GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists. J Clin Endocrinol Metab. 2020;105(8):e2710\u20136. https:\/\/doi.org\/10.1210\/clinem\/dgaa327.","journal-title":"J Clin Endocrinol Metab"},{"key":"767_CR10","unstructured":"Mounjaro [Package Insert]. Indianapolis, IN: Eli Lilly and Company. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf. Accessed 9 Apr 2025."},{"key":"767_CR11","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","volume":"5","author":"K El","year":"2023","unstructured":"El K, Douros JD, Willard FS, et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nat Metab. 2023;5:945\u201354. https:\/\/doi.org\/10.1038\/s42255-023-00811-0.","journal-title":"Nat Metab"},{"key":"767_CR12","doi-asserted-by":"publisher","first-page":"1004044","DOI":"10.3389\/fendo.2022.1004044","volume":"13","author":"B Gallwitz","year":"2022","unstructured":"Gallwitz B. Clinical perspectives on the use of the GIP\/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Front Endocrinol. 2022;13:1004044. https:\/\/doi.org\/10.3389\/fendo.2022.1004044.","journal-title":"Front Endocrinol"},{"issue":"17","key":"767_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140532","volume":"5","author":"FS Willard","year":"2020","unstructured":"Willard FS, Douros JD, Gabe M, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. https:\/\/doi.org\/10.1172\/jci.insight.140532.","journal-title":"JCI Insight"},{"key":"767_CR14","unstructured":"Eli Lilly and Company. A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants. https:\/\/clinicaltrials.gov\/study\/NCT04172987?intr=tirzepatide&rank=83&tab=results. Accessed 9 Apr 2025."},{"issue":"3","key":"767_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","volume":"28","author":"N Sattar","year":"2022","unstructured":"Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01707-4.","journal-title":"Nat Med"},{"issue":"10313","key":"767_CR16","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/s0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (surpass-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(21)02188-7.","journal-title":"Lancet"},{"issue":"3","key":"767_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.12997\/jla.2023.12.3.213","volume":"12","author":"YK Cho","year":"2023","unstructured":"Cho YK, La Lee Y, Jung CH. The cardiovascular effect of Tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist. J Lipid Atheroscler. 2023;12(3):213\u201322. https:\/\/doi.org\/10.12997\/jla.2023.12.3.213.","journal-title":"J Lipid Atheroscler"},{"issue":"5","key":"767_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/nejmoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337. https:\/\/doi.org\/10.1056\/nejmoa2410027.","journal-title":"N Engl J Med"},{"key":"767_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","volume":"267","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024;267:1\u201311. https:\/\/doi.org\/10.1016\/j.ahj.2023.09.007.","journal-title":"Am Heart J"},{"key":"767_CR20","unstructured":"Lilly\u2019s Mounjaro (tirzepatide), a GIP\/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease. Eli Lilly and Company. Media release: July 31, 2025. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated. Accessed 12 Sep 2025."},{"key":"767_CR21","unstructured":"Eli Lilly and Company. SURPASS-CVOT. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes. ClinicalsTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04255433"},{"issue":"1","key":"767_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2416394.","journal-title":"N Engl J Med"},{"issue":"3","key":"767_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"issue":"1","key":"767_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38\u201348. https:\/\/doi.org\/10.1001\/jama.2023.24945.","journal-title":"JAMA"},{"key":"767_CR25","unstructured":"Eli Lilly and Company. Study of Tirzepatide in Healthy Participants. https:\/\/clinicaltrials.gov\/study\/NCT04311424?term=NCT04311424%20&rank=1#study-overview. Accessed 9 Apr 2025."},{"key":"767_CR26","unstructured":"Eli Lilly and Company. A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus. https:\/\/clinicaltrials.gov\/study\/NCT04050553?term=NCT04050553%20&rank=1. Accessed 9 Apr 2025."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00767-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00767-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00767-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:24:04Z","timestamp":1771507444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00767-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["767"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00767-4","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jessica Huston, Dontia Orey, Andrew Ashchi, Andrea Ashchi Lachapelle, Ariana Genovese, Jenna Jackson, Ramsey Ashchi, Towfeeq Ashchi, Majdi Ashchi, David Sutton, Wasim Deeb, and Rebecca F. Goldfaden have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Data sharing is not applicable to this article as no datasets were generated.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Jessica Huston was involved in supervision, data curation, analysis, reviewing, editing, and writing. Dontia Orey, Andrea Ashchi Lachapelle, Andrew Ashchi, Ariana Genovese, Jenna Jackson, Ramsey Ashchi, and Towfeeq Ashchi were involved in data curation, analysis, and writing. Majdi Ashchi, David Sutton, and Wasim Deeb were involved in reviewing and editing. Rebecca Goldfaden was involved in conceptualization, project administration, reviewing and editing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}